LCN2 and myeloid sarcoma: Remarkably, the increase of LCN2 levels in the experimental animal model was reverted by the humanized monoclonal antibody Natalizumab that in humans is used for MS treatment supporting the notion that LCN2 measurement should be included in the diagnostic panel of markers for MS (Marques et al., 2012).